Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.

Literature DB >> 20425339

Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.

Abstract

Acute myelogenous leukemia (AML) is a difficult disease to treat. Novel treatment strategies, including molecular targeted therapy, are being explored. The c-kit receptor represents a potential therapeutic target for AML. The receptor is expressed on more than 10% of blasts in 64% of patients with de novo AML and 95% of those with relapsed AML. It mediates proliferation and anti-apoptotic effects in AML. This review discusses the biology of c-kit in normal and malignant hematopoiesis and the recent clinical trials targeting c-kit in AML.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2006 PMID： 20425339 DOI： 10.1007/s11899-006-0020-9

Source DB: PubMed Journal: Curr Hematol Malig Rep ISSN： 1558-8211 Impact factor: 3.952

50 in total

1. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

Authors: Thomas Kindler; Frank Breitenbuecher; Andreas Marx; Georg Hess; Harald Gschaidmeier; Heinold Gamm; Charles J Kirkpatrick; Christoph Huber; Thomas Fischer
Journal: Blood Date: 2002-12-12 Impact factor: 22.113

Review 2. Early signaling pathways activated by c-Kit in hematopoietic cells.

Authors: D Linnekin
Journal: Int J Biochem Cell Biol Date: 1999-10 Impact factor: 5.085

3. Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells.

Authors: Z Q Ning; J Li; R J Arceci
Journal: Leuk Lymphoma Date: 2001-05

4. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

Authors: Francis J Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
Journal: Blood Date: 2003-03-20 Impact factor: 22.113

5. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.

Authors: Rui Zheng; Kendra Klang; Norbert C Gorin; Donald Small
Journal: Leuk Res Date: 2004-02 Impact factor: 3.156

6. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.

Authors: Florian Heidel; Jorge Cortes; Frank G Rücker; Walter Aulitzky; Laurie Letvak; Thomas Kindler; Christoph Huber; Hartmut Döhner; Hagop Kantarjian; Thomas Fischer
Journal: Cancer Date: 2007-03-01 Impact factor: 6.860

7. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.

Authors: Karsten Spiekermann; Florian Faber; Robert Voswinckel; Wolfgang Hiddemann
Journal: Exp Hematol Date: 2002-07 Impact factor: 3.084

Targeting the c-kit receptor in the treatment of acute myelogenous leukemia.

1. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.

Review 2. Early signaling pathways activated by c-Kit in hematopoietic cells.

3. Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells.

4. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.

5. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML.

6. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.

7. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells.

8. Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia.

9. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group.

10. Soluble c-kit molecule in serum from healthy individuals and patients with haemopoietic disorders.

1. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.

Review 2. Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia.